• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PTGS1 Gene Record

  • Summary
  • Interactions
  • Claims
  • PTGS1 5742 Druggable Genome

    Alternate Names:

    5742
    PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1
    PTGS1
    COX1
    COX3
    PCOX1
    PES-1
    PGG/HS
    PGHS-1
    PGHS1
    PHS1
    PTGHS
    176805
    9604
    ENSG00000095303
    OTTHUMG00000020605
    PA24346
    Prostaglandin G/H synthase 1
    Cyclooxygenase-1
    Prostaglandin H2 synthase 1
    COX-1
    PGH synthase 1
    PHS 1
    P23219
    PGH1_HUMAN
    PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (CYCLOOXYGENASE- 1) (COX-1) (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN H2 SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P23219]
    T60529

    Gene Info:

    Target Subclass 1.14.99.1
    Target Main Class Enzymes
    Target Class Enzymes
    Target Subclass EC:1.14.99.1
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR002007
    Interpro Short Name Haem_peroxidase_animal
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Family
    Uniprot Status Swiss-Prot
    Interpro Name Haem peroxidase, animal
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Sinning C et al., 2008, New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide., J Med Chem
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Hinz et al., 2008, Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man., FASEB J.
    Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
    Bender et al., 2007, Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure., ChemMedChem
    Llorens et al., 2002, Differential binding mode of diverse cyclooxygenase inhibitors., J. Mol. Graph. Model.
    Loll et al., 1996, Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site., Biochemistry
    Warner et al., 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis., Proc. Natl. Acad. Sci. U.S.A.
    Beretta et al., 2005, COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis., Pharmacol. Res.
    Morton et al., 2005, Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis., Res. Vet. Sci.
    Zitova et al., 2010, Analysis of activity and inhibition of oxygen-dependent enzymes by optical respirometry on the LightCycler system., Anal. Biochem.
    Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
    Gupta et al., 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors., Bioorg. Med. Chem. Lett.
    Yu et al., 2013, Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro., Biopharm Drug Dispos
    Martić et al., 2004, Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors., Eur J Med Chem
    Chavez et al., 2003, Valdecoxib: a review., Clin Ther
    Patrignani, 2003, Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease., Thromb. Res.
    Hillarp, 2004, [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]., Lakartidningen
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Verschuren JJ et al., 2013, Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction., Int J Cardiol
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Lepäntalo A et al., 2006, Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients., Thromb Haemost
    Higuchi et al., 2004, Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach., Drugs Exp Clin Res
    Moth et al., 2005, Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1., J. Med. Chem.
    Bobadilla L et al., 2005, Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta., Clin. Exp. Pharmacol. Physiol.
    Kundu et al., 2005, Cyclooxygenase inhibitors modulate NK activities that control metastatic disease., Cancer Immunol. Immunother.
    Fornai et al., 2005, Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice., Gut
    Christ AN et al., 2010, Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases., J Med Chem
    Hanna MM, 2012, New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies., Eur J Med Chem
    Blanco et al., 1999, Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes., J. Rheumatol.
    Ottonello et al., 2009, Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway., Br. J. Pharmacol.
    Kawai, 1998, Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration., Inflamm. Res.
    Kean, 2004, Oxaprozin: kinetic and dynamic profile in the treatment of pain., Curr Med Res Opin
    Yood et al., 2006, The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy., Pharmacoepidemiol Drug Saf
    Zhou et al., 2009, Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug., Biol. Pharm. Bull.
    Gamache et al., 2000, Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy., Inflammation
    Chen et al., 2005, Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors., Bioorg. Med. Chem.
    Young et al., 1996, Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production., Inflamm. Res.
    Cappon et al., 2003, Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure., Birth Defects Res. B Dev. Reprod. Toxicol.
    James et al., 2007, Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure., Lipids
    Brutzkus JC et al., 2020, Naproxen,
    Stevenson, 2004, Aspirin and NSAID sensitivity., Immunol Allergy Clin North Am
    Schmidt et al., 1991, Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F)., J. Biol. Chem.
    Josephs et al., 1999, Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility., J. Surg. Res.
    Poggi et al., 2006, Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus., J Clin Pharmacol
    Wang H et al., 1999, Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries., J Nat Prod
    Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Takeuchi et al., 2006, Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease., Clin. Gastroenterol. Hepatol.
    Bensen et al., 1998, Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis., Can Fam Physician
    Giuliano et al., 2001, Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation., Eur. J. Pharmacol.
    Cipollone et al., 1995, Effects of nabumetone on prostanoid biosynthesis in humans., Clin. Pharmacol. Ther.
    Wilson et al., 2004, Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs., Am. J. Vet. Res.
    Hirate et al., 2006, Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors., Neurosci. Res.
    Riendeau et al., 1997, Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor., Br. J. Pharmacol.
    Glaser et al., 1995, Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1., Eur. J. Pharmacol.
    Campbell et al., 2002, The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon., Equine Vet. J.
    Bugajski et al., 2001, Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion., J. Physiol. Pharmacol.
    Veiga et al., 2004, Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats., Life Sci.
    Raju et al., 2002, Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam., Mol. Cell. Biochem.
    Fackovcova et al., 2000, Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance., Bratisl Lek Listy
    Koeberle A et al., 2014, SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase., J Med Chem
    Kurahashi et al., 2001, Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites., J. Cardiovasc. Pharmacol.
    Klegeris et al., Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity., Neurobiol. Aging
    Dröge et al., Alternative splicing of cyclooxygenase-1 mRNA in the human iris., Ophthalmic Res.
    Basselin et al., 2007, Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats., Neurochem. Res.
    Rieke et al., 1999, The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors., J. Biol. Chem.
    Nivsarkar et al., Cyclooxygenase inhibitors: a novel direction for Alzheimer's management., Pharmacol Rep
    Hewett et al., 2000, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture., J. Pharmacol. Exp. Ther.
    Waterbury et al., 2006, Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium., Curr Med Res Opin
    Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
    Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
    Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
    Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
    Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
    Yamada et al., 1997, Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages., J. Pharmacol. Exp. Ther.
    Lúcio et al., 2006, Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity., Med Chem
    Ozgocmen et al., 2005, In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis., Ann. Clin. Lab. Sci.
    Lora et al., 1997, Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin., Prostaglandins Leukot. Essent. Fatty Acids
    Kothekar et al., Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study., Indian J. Biochem. Biophys.
    Parsadaniantz et al., 2000, Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat., J. Neuroendocrinol.
    Levoin et al., 2004, Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen., Biochem. Pharmacol.
    Zúñiga et al., 2003, Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo., Biol. Res.
    Lashbrook et al., 1999, Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats., Pain
    Uzan, 2005, The unexpected side effects of new nonsteroidal anti-inflammatory drugs., Expert Opin Emerg Drugs
    Dionne et al., Analgesia and COX-2 inhibition., Clin. Exp. Rheumatol.
    Blais et al., 2005, Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli., J. Neurochem.
    Bosch-Marcè et al., 1999, Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites., Gastroenterology
    Kämpfer et al., 2003, Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair., J. Invest. Dermatol.
    Calkin et al., 2002, Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2., J. Clin. Endocrinol. Metab.
    Hinz et al., 2003, Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac., Clin. Pharmacol. Ther.
    Kirchheiner et al., 2003, Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans., Br J Clin Pharmacol
    Nurtjahja-Tjendraputra et al., 2003, Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger., Thromb. Res.
    Burdan et al., 2005, Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats., Toxicology
    Capasso et al., 1997, Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum., Eur. J. Pharmacol.
    Capasso, 1999, Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues., Neuropharmacology
    Kennedy et al., 2003, Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility., Reprod. Biol. Endocrinol.
    Ringbom T et al., 1998, Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis., J Nat Prod
    Sinniah et al., 2001, Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid., Clin. Nephrol.
    Cryer et al., 1998, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs., Am. J. Med.
    Joo et al., 2006, Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models., Mol. Pharmacol.
    Laudanno et al., 1998, [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]., Acta Gastroenterol. Latinoam.
    Gierse et al., 1995, Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase., Biochem. J.
    Kammerl et al., 2001, Inhibition of COX-2 counteracts the effects of diuretics in rats., Kidney Int.
    Gao LC et al., 2015, Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients., Eur J Clin Pharmacol
  • SUPROFEN   PTGS1

    Interaction Score: 4.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    17477341 11752352 11885959 8652509 10377455


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • SALSALATE   PTGS1

    Interaction Score: 3.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    15242723 1680855 11752352 10452868


    Sources:
    TdgClinicalTrial TEND TTD

  • OXAPROZIN   PTGS1

    Interaction Score: 3.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    19338579 9831331 15324530 17024689 19952416


    Sources:
    ChemblInteractions

  • BROMFENAC   PTGS1

    Interaction Score: 2.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Bromfenac
    Novel drug target Established target
    Trial Name ISV-101

    PMIDs:
    11752352 16846546


    Sources:
    TdgClinicalTrial TEND TTD

  • KETOROLAC   PTGS1

    Interaction Score: 2.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ketorolac tromethamine ophthalmic solution,Acuvail
    Novel drug target Established target
    Trial Name ROX-828

    PMIDs:
    10422661 16262557 11695255 16277613 10220509


    Sources:
    TdgClinicalTrial TEND

  • ETODOLAC   PTGS1

    Interaction Score: 2.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name VT-122
    Novel drug target Established target

    PMIDs:
    15198222 16473424 9146894 8566109 12358053


    Sources:
    TdgClinicalTrial TEND

  • TOLMETIN   PTGS1

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    16182428 9253954 10465690 14613550


    Sources:
    TdgClinicalTrial TEND

  • KETOPROFEN   PTGS1

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ketoprofen in Transfersome gel, IDEA-033,Diractin
    Novel drug target Established target
    Trial Name ketoprofen transdermal patch, EN3269

    PMIDs:
    10929089 14987823 15476667 11811354 14513718


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • NEPAFENAC   PTGS1

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    10850857


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • BALSALAZIDE   PTGS1

    Interaction Score: 1.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name balsalazide disodium,Colazal, Giazo

    PMIDs:
    12950415 19743890 17016423 17139284 11752352


    Sources:
    TdgClinicalTrial TTD

  • FLURBIPROFEN   PTGS1

    Interaction Score: 1.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    11811354 12392782 12711844 17562170 10358065 19066416 10773011


    Sources:
    ChemblInteractions TEND

  • FENOPROFEN   PTGS1

    Interaction Score: 1.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    17050798


    Sources:
    TdgClinicalTrial TEND

  • DIFLUNISAL   PTGS1

    Interaction Score: 1.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes
    Trial Name CRx-401

    PMIDs:
    15755648 8737748 12852483


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • TENOXICAM   PTGS1

    Interaction Score: 1.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    9152412 17017983 15943176 9175172 11563332


    Sources:
    TdgClinicalTrial TEND

  • (+)-EPICATECHIN   PTGS1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • GINGER   PTGS1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14693173


    Sources:
    NCI

  • E163   PTGS1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10075763


    Sources:
    DTC

  • NABUMETONE   PTGS1

    Interaction Score: 0.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16469680 9481468 11525777 7554708


    Sources:
    TdgClinicalTrial TEND

  • PIROXICAM   PTGS1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    11785774 15464832 11952155 11153163 10381057


    Sources:
    ChemblInteractions TEND TTD

  • LATANOPROST   PTGS1

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25339146


    Sources:
    PharmGKB

  • NAPROXCINOD   PTGS1

    Interaction Score: 0.68

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes
    Trial Name Naproxcinod

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • MEFENAMIC ACID   PTGS1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    11316248 9626023 16223958 9773153 7832763


    Sources:
    ChemblInteractions

  • AMINOSALICYLATE SODIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • IMRECOXIB   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DICLOFENAC EPOLAMINE   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • VB-201   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name VB-201
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • BROMFENAC SODIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FENOPROFEN CALCIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FLURBIPROFEN SODIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FENBUFEN   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NAPROXEN ETEMESIL   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DICLOFENAC POTASSIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • IBUPROFEN SODIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AMINOSALICYLATE POTASSIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CURCUMIN PYRAZOLE   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24920381


    Sources:
    DTC

  • NAPROXEN   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor
    Trial Name MT 100

    PMIDs:
    17541796 30247840


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • OXAPROZIN POTASSIUM   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • IBUPROFEN LYSINE   PTGS1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SULINDAC   PTGS1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    10372826 10484067 12586211 10626810 12512695


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • IBUPROFEN   PTGS1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HZT-501, ibuprofen + famotidine,Duexa
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    23651359 14741265 23536207 14987823 11752352 12852704 14592549 15575422 25502615


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • DICLOFENAC   PTGS1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name transdermal diclofenac
    Trial Name PRO-571, diclofenac potassium
    Trial Name NanoEmulsion (diclofenac)

    PMIDs:
    12713596 12414874 12966366 11752352 12852704 12534640


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • INDOMETHACIN   PTGS1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    15700751 15887968 15743404 15891886 15831902 20684598 22818041 23651359 10381057


    Sources:
    DTC ChemblInteractions TEND

  • KETOROLAC TROMETHAMINE   PTGS1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TOLMETIN SODIUM   PTGS1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NAPROXEN SODIUM   PTGS1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYLBUTAZONE   PTGS1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    15939622 15563928 19849999


    Sources:
    ChemblInteractions

  • MESALAMINE   PTGS1

    Interaction Score: 0.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MAX-002
    Novel drug target Established target
    Trial Name mesalamine,Pentasa, Canasa, Asacol

    PMIDs:
    12950415 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • OLSALAZINE SODIUM   PTGS1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DERSALAZINE   PTGS1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name dersalazine sodium

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • BISMUTH SUBSALICYLATE   PTGS1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BALSALAZIDE DISODIUM   PTGS1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ACETAMINOPHEN   PTGS1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor
    Trial Name PTI-701

    PMIDs:
    19053765 11752352 17884974


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND

  • DICLOFENAC SODIUM   PTGS1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • URSOLIC ACID   PTGS1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9784154


    Sources:
    DTC

  • MECLOFENAMATE SODIUM   PTGS1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SULFASALAZINE   PTGS1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor
    Novel drug target Established target

    PMIDs:
    12950415


    Sources:
    TdgClinicalTrial ChemblInteractions

  • ASPIRIN   PTGS1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    23651359 22940005 20938371 16493486


    Sources:
    DTC ChemblInteractions TEND PharmGKB

  • CLOPIDOGREL   PTGS1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22940005


    Sources:
    PharmGKB

  • OXYPHENBUTAZONE   PTGS1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclooxygenase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROCHLOROTHIAZIDE   PTGS1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11703585


    Sources:
    NCI

  • CURCUMIN   PTGS1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24920381


    Sources:
    DTC TTD

  • Ensembl: ENSG00000095303

    • Version: 101_38

    Alternate Names:
    PTGS1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P23219

    • Version: 01-August-2011

    Alternate Names:
    PGH1_HUMAN Uniprot Id
    PTGS1 Gene Symbol
    5742 Entrez Gene Id

    Gene Info:
    Target Subclass 1.14.99.1
    Target Main Class Enzymes

    Publications:

  • RussLampel: ENSG00000095303

    • Version: 26-July-2011

    Alternate Names:
    PROSTAGLANDIN G/H SYNTHASE 1 PRECURSOR (EC 1.14.99.1) (CYCLOOXYGENASE- 1) (COX-1) (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN H2 SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P23219] Description
    ENSG00000095303 Ensembl Gene Id
    PTGS1 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P23219

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000095303 Ensembl Gene Id
    PTGS1 Uniprot Gene Name
    PGH1_HUMAN Uniprot Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR002007
    Interpro Short Name Haem_peroxidase_animal

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P23219

    • Version: January-2014

    Alternate Names:
    PTGS1 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.14.99.1

    Publications:

  • PharmGKB: PTGS1

    • Version: 18-August-2020

    Alternate Names:
    PA24346 PharmGKB ID

    Gene Info:

    Publications:
    Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
    St Germaine CG et al., 2010, Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs., Am J Cardiol
    Gao LC et al., 2015, Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients., Eur J Clin Pharmacol

  • TTD: Prostaglandin G/H synthase 1

    • Version: 2020.06.01

    Alternate Names:
    COX-1 TTD Gene Abbreviation
    T60529 TTD Target ID

    Gene Info:

    Publications:
    Cohen MP et al., 2013, Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats., Physiol Rep

  • NCI: PTGS1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Kammerl et al., 2001, Inhibition of COX-2 counteracts the effects of diuretics in rats., Kidney Int.
    Giannitrapani et al., 2007, Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C., Eur J Gastroenterol Hepatol
    Nurtjahja-Tjendraputra et al., 2003, Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger., Thromb. Res.

  • DTC: PTGS1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
    Wang H et al., 1999, Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries., J Nat Prod
    Sinning C et al., 2008, New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide., J Med Chem

  • ChemblInteractions: COX1

    • Version: chembl_23

    Alternate Names:
    COX1 GENE_SYMBOL
    PTGS1 GENE_SYMBOL
    Prostaglandin G/H synthase 1 UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000095303

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000095303 Gene Symbol
    PTGS1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: PTGS1

    • Version: 01-February-2022

    Alternate Names:
    Prostaglandin G/H synthase 1 Gene Name
    P23219 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21